Quantitative Investment Management LLC reduced its holdings in shares of Zoetis Inc (NYSE:ZTS) by 77.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,700 shares of the company’s stock after selling 377,300 shares during the quarter. Quantitative Investment Management LLC’s holdings in Zoetis were worth $7,974,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of ZTS. Polen Capital Management LLC acquired a new position in shares of Zoetis during the fourth quarter valued at about $285,967,000. Bessemer Group Inc. grew its holdings in shares of Zoetis by 231,590.8% during the fourth quarter. Bessemer Group Inc. now owns 2,117,654 shares of the company’s stock valued at $152,557,000 after buying an additional 2,116,740 shares during the last quarter. BlackRock Inc. lifted its position in shares of Zoetis by 3.8% during the fourth quarter. BlackRock Inc. now owns 38,485,542 shares of the company’s stock valued at $2,772,498,000 after purchasing an additional 1,394,156 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Zoetis by 111.3% during the fourth quarter. Acadian Asset Management LLC now owns 1,709,352 shares of the company’s stock valued at $123,143,000 after purchasing an additional 900,261 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Zoetis by 292.2% during the fourth quarter. Victory Capital Management Inc. now owns 1,063,051 shares of the company’s stock valued at $76,583,000 after purchasing an additional 792,000 shares in the last quarter. Hedge funds and other institutional investors own 92.45% of the company’s stock.
In other news, insider Roman Trawicki sold 23,885 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $82.00, for a total value of $1,958,570.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Roxanne Lagano sold 35,663 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the completion of the sale, the executive vice president now directly owns 49,919 shares in the company, valued at approximately $4,044,437.38. The disclosure for this sale can be found here. In the last ninety days, insiders sold 97,001 shares of company stock worth $7,882,428. Insiders own 0.31% of the company’s stock.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.66 by $0.03. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.47 earnings per share. equities analysts forecast that Zoetis Inc will post 3.04 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be given a $0.126 dividend. This represents a $0.50 annualized dividend and a yield of 0.60%. The ex-dividend date is Thursday, April 19th. Zoetis’s dividend payout ratio is 28.57%.
ZTS has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price target on the stock. in a research report on Saturday, January 13th. Citigroup raised shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price target on the stock in a research report on Thursday, January 4th. BMO Capital Markets reissued a “hold” rating on shares of Zoetis in a research report on Monday, January 8th. Cowen set a $80.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, November 17th. Finally, Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target on the stock in a research report on Wednesday, November 29th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $80.28.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.